The global alzheimer’s therapeutics market is expected to reach USD 6.4 billion in 2024, according to a new report by Grand View Research. Some primary factors driving the market growth includes rising government initiatives in order to raise awareness levels among people.
Growing knowledge about the Alzheimer’s disease (AD) and its high prevalence and incidence in developing economies are few of the major drivers supporting the market growth. Several governments, nonprofit, and private organizations worldwide are actively engaged in increasing people’s awareness regarding progressive AD, such as Alzheimer’s Association, the Alzheimer’s Society of Canada, Alzheimer’s Europe organization, and various other small organizations.
Furthermore, the increased government funding for providing better care and support to the people with partial dementia is another important factor anticipated to enlarge market growth. For instance, organizations like Florida Department of Health, the National Institute of Health, and Alzheimer’s Association in partnership with other private and government organizations provide funds to the research centers.
The presence of various pipeline drugs is anticipated to provide the market with potential growth opportunities. For instance, LMTX by TauRx Pharmaceutical Ltd.; idalopirdine (Lu AE58054) by Lundbeck; crenezumab by AC Immune SA; and BAN2401 by Eisai
Moreover, novel therapeutics with minimal dosage requirement has been introduced resulting in cost-effective alternatives, which is further expected to boost the market growth. For instance, Namzaric by Actavis was developed in two forms: 10 mg and 28 mg. 10 mg requires to be administered twice a day, while 28 mg requires to be administered once in a day.
Browse full research report on Global Alzheimer’s Therapeutics Market: http://www.grandviewresearch.com/industry-analysis/alzheimers-therapeutics-market
Further Key Findings from the Study Suggest:
Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the Alzheimer’s therapeutics market on the basis of drug class and region:
Alzheimer’s Therapeutics Market Drug Outlook (Market Revenue in USD Million, 2013 - 2024)
Alzheimer’s Therapeutics Market Regional Outlook, (Market Revenue in USD Million, 2013 - 2024)
Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-alzheimers-therapeutics-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Corporate Sales Specialist, USA
Grand View Research, Inc
All rights reserved• This document may not be used, copied nor changed without explicit consent of the author.